Top Qs
Timeline
Chat
Perspective
Tochergamine
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
Tochergamine, also known as 621 I.S. or as N,N-diethyl-N′-(1,2,3,4-tetrahydronaphthyl)glycinamide, is an oxytocic drug related to ergometrine which does not appear to have been marketed.[1][2]
It was reported to be effective as an oxytocic agent in animal studies, with oxytocic activity equivalent to that of ergometrine.[3] In addition, the drug was reported to be effective in clinical studies at doses of 2 to 6 mg parenterally.[2][4][5] However, subsequent research found that it was inactive on the intact human uterus at doses of up to 20 mg, and further investigation of tochergamine was abandoned.[3][2]
Tochergamine has a simplified lysergamide-like chemical structure, with a 1-aminotetralin ring system, and is structurally related to lysergamides like ergometrine and LSD.[1][6] However, it is not technically a partial ergoline or lysergamide, only partial ergoline-like, as its structural features differ in certain regards from those of ergolines and lysergamides.[1][6] The oxytocic effects of lysergamides like ergometrine are thought to most likely be mediated by agonism of serotonin 5-HT2 receptors in uterine smooth muscle tissue.[7][8]
Tochergamine was first described in the scientific literature in 1951.[4] It was developed by Daniel Bovet and colleagues at the Istituto Superiore di Sanità in Rome, Italy.[2][4] The drug was known as tochergamina in Italy.[4] It was clinically studied as an oxytocic agent in the 1950s.[2][4][9][5][10]
Analogues of tochergamine, for instance the 2-aminotetralin positional isomer, have also been described, and have likewise shown oxytocic and lysergic acid-like activity.[11]
Remove ads
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads